
Potential therapeutic intervention
ALO17
ATIC
CLTC
EEF1G
MAP7
MSN
PABPC1
RNF213
TPM3
TRAF1
NPM1
PABPC4
NCOR2
NFkB2
CAPRIN1
ILF3
STAT3
PCM1
ATXN2L
PICALM
KHDRBS1
TFG
TRA@
TRD@
VAV1
CTLA4
ICOS
ITK
FOXK2
ATXN1
TBL1XR1
IKZF2
FYN
PTPR
SELENOI
LINC-PINT
CD53
MYB
ETV6
EHD1
ALK
TYK2
ROS1
FRK
JAK2
LCK
GPR128
NECTIN2
GSS
MYO1F
S100A7
SF1
STAP2
THAP4
CD28
FER
SYK
TP63
BCL11B
ERBB4
BACH2
TRAF3IP2
CPN2
ABL1
DUSP22
PDGFRB
MBNL1
FGFR3
CAPN12
ALK inhibitors (crizotinib, alectinib)
JAK inhibitor, TYK2 inhibitor
(deucravacitnib)
ROS1 inhibitor (JNJ-ROS1i-A)
Kinase inhibitor (dasatinib)
JAK inhibitor (ruxolitinib, tofacitinib,
gandotinib, momelotinib),
dual SYK and JAK inhibitor (cerdulatinib)
RAC1 inhibitor (azathioprine)
CTLA4 blockade (Ipilimumab)
JAK3 inhibitor (tofacitinib),
dual SYK and JAK inhibitor (cerdulatinib)
Inhibitor of ERBB-family kinases (lapatinib)
IkB kinase inhibtors
ALCL ALK+
ALCL ALK-
TFH-PTCL/AITL
ATLL
PTCL NOS
CTCL
autres